VHH Antibodies Derived from Camelids Show Potential for Targeted Therapies Despite Stability Challenges

Single-domain antibodies, known as VHH antibodies, demonstrate significant biological activity and versatility due to their modular structure. These antibodies, derived from camelid species, are smaller than conventional antibodies and possess unique properties that make them suitable for various applications in biotechnology and medicine. Their compact size allows for easier engineering and customization, enabling researchers to develop targeted therapies with precision.

Despite their promising capabilities, VHH antibodies also present challenges in development and application. Their small size can lead to issues such as reduced stability or shorter half-life compared to traditional antibodies. Researchers continue to explore strategies to address these limitations while leveraging the advantages of these single-domain antibodies in therapeutic settings. The ongoing study of VHH antibodies highlights their potential role in advancing medical treatments while emphasizing the need for continued innovation in overcoming associated obstacles.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 9, 2026

Author

GOAI